PBYIPosition Budget Year Inquiry
Copyright 1988-2018 AcronymFinder.com, All rights reserved.
References in periodicals archive ?
(NASDAQ: PBYI) shares moved upwards by 23.2% to $11.35.
(NASDAQ: PBYI) has presented updated interim results from a Phase II clinical trial of Puma's drug neratinib at the American Society of Clinical Oncology 2019 annual meeting in Chicago, the company said.
Puma Biotechnology (PBYI) downgraded to Underweight from Equal Weight at Barclays, to Underweight from Overweight at JPMorgan, and to Underperform from Buy at BofA/Merrill.
Puma Biotechnology Inc (NASDAQ: PBYI)'s second-quarter revenues climbed 6.1% to $53.9 million and the net loss narrowed from $1.17 per share to 97 cents per share.
United States-based Puma Biotechnology Inc (Nasdaq: PBYI) has signed a license agreement with France-based Pierre Fabre, it was reported yesterday.
Celcuity (CELC) announced a clinical trial agreement with Puma Biotechnology (PBYI) and West Cancer Center, to conduct a Phase II clinical trial.
Meanwhile, top gainers in the sector included Puma Biotechnology, Inc.(NASDAQ: PBYI), up 27%, and Cutera, Inc.(NASDAQ: CUTR), up 22%.
RBC Capital analyst Kennen MacKay thinks the data presented this morning by Roche's (RHHBY) Genentech could pressure shares of Puma Biotechnology (PBYI) today.
* Puma Biotechnology Inc (NASDAQ: PBYI) rose 30.7% to $12.04 after the company reported better-than-expected Q2 EPS and sales results.
- US-based biopharmaceutical company Puma biotechnology, Inc.'s (NASDAQ: PBYI) licensing partner Specialised Therapeutics Asia has received marketing authorization from Australia's Therapeutic Goods Administration to commercialise Nerlynx (neratinib) in Australia for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer following adjuvant trastuzumab based therapy, the company said.
Puma Biotechnology Inc (NASDAQ: PBYI) and CANbridge Life Sciences have entered into an exclusive licensing agreement to develop and commercialise Nerlynx (neratinib) in China, Taiwan, Hong Kong and Macao (collectively, Greater China), the companies announced on Friday.
Shares of Puma Biotechnology, Inc.(NASDAQ: PBYI) got a boost, shooting up 20% to $11.10 after the company reported better-than-expected Q2 EPS and sales results.